The Top 5 Analyst Questions From USANA's Q4 Earnings Call

USANA’s fourth quarter results met Wall Street’s expectations on revenue and surpassed estimates for non-GAAP profit, yet the market responded negatively. Management attributed this to ongoing margin pressures and a continued shift in business mix, particularly the growing role of lower-margin brands like Rise Wellness and Hiya. CEO Kevin Guest, who resumed his leadership role, highlighted operational changes and a strategic pivot toward omnichannel distribution and scientific product innovation. He acknowledged headwinds, saying, “Our core business has faced year-over-year sales declines, but we are seeing encouraging signs of stabilization.”

Is now the time to buy USNA? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From USANA’s Q4 Earnings Call

• Anthony Lebiedzinski (Sidoti & Company) asked about the wide revenue and EPS guidance range. CFO Doug Hekking explained that uncertainty in retail order timing for Rise Wellness and Hiya’s early-stage expansion made forecasting difficult.
• Lebiedzinski (Sidoti & Company) questioned seasonality and revenue ramp expectations. Chief Commercial Officer Brent Neidig described stronger first-half momentum from Chinese New Year promotions and retail launches, with a typical summer lull in Q3.
• Lebiedzinski (Sidoti & Company) inquired about cost realignment and gross margin prospects. Hekking cited a 10% workforce reduction and $10 million in annual savings, but noted mix shift toward lower-margin brands would limit gross margin gains.
• Lebiedzinski (Sidoti & Company) sought details on technology investments. CEO Kevin Guest emphasized leveraging AI and external platforms to accelerate customer engagement and brand relevance, with further details to come as plans mature.
• Ivan Feinseth (Tigress Financial) asked about integrating health technology into products. Chief Science Officer Kathryn Armstrong stressed the need to balance personalized health tools with scientific rigor and real physiological benefits.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will watch (1) the pace of retail distribution and international expansion for Hiya and Rise Wellness, (2) whether technology upgrades and AI initiatives translate into improved customer engagement and operational efficiency, and (3) the company’s ability to stabilize gross margins despite a shifting business mix. Sustained momentum in omnichannel partnerships will also be a key metric of success.

USANA currently trades at $21.80, up from $20.66 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.